Mission 04 · MOTS-c / NAD+ / peptide research
Same conversation.
Different experiments.
MOTS-c vs NAD+ vs Epitalon: the names often travel together. The evidence does not.
About 3 min · Study settings kept in view
Mission log / 01
MOTS-c vs NAD+: start with who was studied
Added MOTS-c improved physical performance in mice. Oral NMN improved muscle insulin sensitivity in prediabetic, postmenopausal women. Running in a mouse and glucose handling in human muscle are different outcomes.
The human MOTS-c dialysis cohort observed a naturally circulating peptide; it did not give anyone a treatment. Oral NMN and NR trials did administer a substance to people. That is a meaningful difference in how directly a study can answer a treatment question.
The experiments, side by side.
| Substance & setting | Observed in this study | Still unproved |
|---|---|---|
| Epitalon Human cells in culture | Telomeres lengthened in normal and breast-cancer cells | Human cancer risk, safety or longer life |
| Epitalon Female SHR mice | Maximum lifespan rose; mean lifespan did not | A general human lifespan benefit |
| Added MOTS-c Mice | Physical performance improved | Human treatment benefit or safety |
| Natural MOTS-c People receiving hemodialysis | Higher levels associated with death and non-fatal cardiovascular events | What giving the peptide would do |
| Oral NR Healthy overweight adults | Whole-blood NAD+ increased | Disease prevention or longer life |
| Oral NMN Prediabetic, postmenopausal women | Muscle insulin sensitivity improved; body composition and HbA1c did not | A general anti-aging effect |
Mission log / 02
Epithalon vs NMN: the names need unpacking
Epithalon is another spelling of Epitalon. Epithalamin is a different substance, the pineal extract used in the older-person follow-up. That study cannot become a human lifespan result for synthetic Epitalon.
NMN is not NAD+; it is a precursor. The NMN walking study is a human intervention trial. The Epitalon telomere study used cultured cells, including breast-cancer cells. Neither result establishes slower human aging.
Mission log / 03
A bigger evidence base is still a bounded one
The review of human NAD+ precursor trials gives NR and NMN more direct human intervention evidence than the other research discussed here. It also finds limited efficacy and inconsistent broader outcomes.
There is no head-to-head trial in this collection declaring a winner. Putting substances together would not combine their evidence or establish that a combination is safe. The Epitalon, MOTS-c and NAD+ guides keep each set of limits close to its findings.
